Is Design Therapeutics, Inc. profitable?

Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.

What is Design Therapeutics, Inc.'s earnings per share?

Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.

Where does Design Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Design Therapeutics, Inc. DSGN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$0—	$0—	——	——
Research and development	$59.13M+33.3%	$44.35M-22.3%	$57.06M+17.4%	$48.61M+96.2%
General and administrative	$20.34M+12.8%	$18.03M-14.6%	$21.13M+11.3%	$18.98M+71.7%
Other operating expenses	$79.47M+27.4%	$62.38M-20.2%	$78.19M+15.7%	$67.59M+88.6%
Total operating expenses	$79.47M+27.4%	$62.38M-20.2%	$78.19M+15.7%	$67.59M+88.6%
Operating income	-$79.47M-27.4%	-$62.38M+20.2%	-$78.19M-15.7%	-$67.59M-88.6%
Interest income	$9.68M-24.4%	$12.8M+13.0%	$11.33M—	——
Other income (expense), net	——	——	$11.33M+164%	$4.29M+1,338%
Net income	-$69.79M-40.7%	-$49.59M+25.8%	-$66.86M-5.6%	-$63.31M-78.2%
Diluted earnings per share	-$1.22-38.6%	-$0.88+26.7%	-$1.20-5.3%	-$1.14-32.6%
Basic earnings per share	-$1.22-38.6%	-$0.88+26.7%	-$1.20-5.3%	-$1.14-48.1%
Weighted-average shares, diluted	227.9M+0.7%	226.3M+1.1%	223.8M+0.5%	222.7M+28.1%
Weighted-average shares, basic	227.9M+0.7%	226.3M+1.1%	223.8M+0.5%	222.7M—
EBIT	-$79.47M-27.4%	-$62.38M+20.2%	-$78.19M-15.7%	-$67.59M-88.6%
EBITDA	-$78.85M-27.6%	-$61.79M+20.4%	-$77.65M-15.6%	-$67.19M-88.2%
EBITDA	-$78.85M-27.6%	-$61.79M+20.4%	-$77.65M-15.6%	-$67.19M-88.2%
EBIT	-$79.47M-27.4%	-$62.38M+20.2%	-$78.19M-15.7%	-$67.59M-88.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Design Therapeutics, Inc. profitable?: Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
What is Design Therapeutics, Inc.'s earnings per share?: Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
Where does Design Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.